Hot Features
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma... Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson’s disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson’s disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.36 | 4.46650124069 | 8.06 | 8.49 | 7.88 | 89497 | 8.17692075 | CS |
| 4 | 0.42 | 5.25 | 8 | 8.9 | 7.84 | 110491 | 8.40957867 | CS |
| 12 | 2.23 | 36.0258481422 | 6.19 | 8.9 | 6.04 | 89578 | 7.59492385 | CS |
| 26 | 2.38 | 39.4039735099 | 6.04 | 8.9 | 5.66 | 89006 | 6.82338618 | CS |
| 52 | 2.62 | 45.1724137931 | 5.8 | 8.9 | 5.66 | 73634 | 6.54314817 | CS |
| 156 | 3.57 | 73.6082474227 | 4.85 | 8.9 | 4.35 | 71128 | 5.80462716 | CS |
| 260 | 3.13 | 59.168241966 | 5.29 | 8.9 | 4.28 | 121763 | 5.46144935 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.